Sumitomo Pharma Co., Ltd.
57 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
Previously recorded as Sumitomo Dainippon Pharma Co., Ltd. (to 2022)
10
Ending by 2030
May 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for 1,4-disubstituted imidazole derivative (US 11,661,397) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 2 fees due Dec 9 to 18, 2026 · next Dec 9
- 3 fees due Jan 2 to 18, 2027 · next Jan 2
- 5 fees due Feb 8 to 28, 2027 · next Feb 8
- 3 fees due Mar 1 to 12, 2027 · next Mar 1
- 4 fees due Apr 10 to 24, 2027 · next Apr 10
- 1 fee due Jun 5, 2027The maintenance fee for Vaccine adjuvant formulation (US 11,833,247) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 4 fees due Aug 16 to 27, 2027 · next Aug 16
- 3 fees due Sep 12 to 24, 2027 · next Sep 12
- 5 fees due Oct 12 to 28, 2027 · next Oct 12
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
- 5 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,980,316 | Stable Tablet Containing Droxidopa In force · High confidence | In force | High confidence | |
| US 8,710,057 | Imidazo[1,2-b]pyridazine and Pyrazolo[1,5-a]pyrimidine Derivatives and Their Use as Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 7,750,007 | Imidazo[1,2-beta]pyridazine and PYRAZOLO[1,5-Alpha]PYRIMIDINE Derivatives and Their Use as Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,067,413 | 9-Substituted-8-OXO-ADENINE Compounds as Toll-Like Receptor (TLR7 ) Modulators In force · High confidence | In force | High confidence | |
| US 7,906,510 | Amide Derivative and Pharmaceutical Composition Containing the Same In force · High confidence | In force | High confidence | |
| US 8,178,102 | Emulsified composition for dilution and cancer vaccine composition In force · From the USPTO record | In force | From the USPTO record | |
| US 8,471,038 | Novel Bicyclic Heterocyclic Compound In force · High confidence | In force | High confidence | |
| US 9,533,978 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases In force · Medium confidence | In force | Medium confidence | |
| US 8,598,370 | Process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine In force · From the USPTO record | In force | From the USPTO record | |
| US 8,933,229 | 8-Azabicyclo[3.2.1]OCTANE-8-Carboxamide Derivative In force · High confidence | In force | High confidence |
Also on record, not counted in the 138: 57 patents in force now held by others · 17 lapsed for an unpaid fee · 21 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
52 pending · 17 abandoned · 24 no status recorded